Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EPS (Weighted Average and Diluted): 2021-2025

Historic EPS (Weighted Average and Diluted) for Benitec Biopharma (BNTC) over the last 4 years, with Jun 2025 value amounting to -$0.21.

  • Benitec Biopharma's EPS (Weighted Average and Diluted) fell 90.91% to -$0.21 in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.03, marking a year-over-year increase of 82.92%. This contributed to the annual value of -$1.05 for FY2025, which is 13.93% up from last year.
  • Per Benitec Biopharma's latest filing, its EPS (Weighted Average and Diluted) stood at -$0.21 for Q2 2025, which was up 44.74% from -$0.38 recorded in Q1 2025.
  • Benitec Biopharma's EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.11 during Q2 2024, with a 5-year trough of -$36.27 in Q2 2022.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$1.24, with a median of -$0.32 in 2024.
  • In the last 5 years, Benitec Biopharma's EPS (Weighted Average and Diluted) plummeted by 3,940.32% in 2022 and then soared by 95.85% in 2024.
  • Over the past 5 years, Benitec Biopharma's EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.59 in 2021, then tumbled by 466.10% to -$3.34 in 2022, then climbed by 20.96% to -$2.64 in 2023, then soared by 90.15% to -$0.26 in 2024, then tumbled by 90.91% to -$0.21 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.21 in Q2 2025, compared to -$0.38 in Q1 2025 and -$0.26 in Q4 2024.